Annual Think Pink, Key To The Cure Events A Huge Success
UC cancer programs and the Barrett Cancer Center were presented a check this month for $21,819 from Saks Fifth Avenue for funds raised during the September 2003
Key To The Cure
national campaign.
"We appreciate the generous support that Saks provides to UC cancer programs and the Barrett Cancer Center," said UC President Nancy L. Zimpher. "Saks' annual
Key To The Cure
campaign is an exemplary effort to reach out and make a difference in the community. UC is very fortunate to have Saks as a partner in the fight against cancer."
Saks Fifth Avenue launched
Key To The Cure
, a charitable initiative to fight women's cancers in 2003. Building upon the success of its Fashion Targets Breast Cancer shopping weekend begun in 1999, Saks Fifth Avenue expanded the program to include all women's cancers including ovarian, cervical, uterine and breast.
For the 2003
Key To The Cure
event, Saks Fifth Avenue teamed up with the Entertainment Industry Foundation (EIF), an organization formed during World War II to unite the giving power of the Hollywood studios and celebrities. Saks' downtown store donated 2 percent of all sales September 17-20 to UC Cancer Programs and The Barrett Cancer Center.
UC Cancer Programs and The Barrett Cancer Center hosted its annual Think Pink educational luncheon to kick off the national shopping campaign. The luncheon raised $118,000 for breast cancer research at UC Cancer Programs and The Barrett Cancer Center.
In addition to the funds raised at the Think Pink luncheon and the
Key To The Cure
shopping weekend, employees at Saks in Cincinnati donated $1280.
Present at the check passing were Ina Levinson, general manager of Saks, Cincinnati; UC President Nancy L. Zimpher; Eileen Barrett, co-chair, 2003 Think Pink event; and Cecilia Fenoglio-Preiser, MD, director, UC Cancer Programs. Rhonda Sheakley, co-chair of the 2003 Think Pink event, was not able to attend.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.